$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

Abstract

Ovarian cancer treatment remains a challenge and targeting cancer stem cells presents a promising strategy. Niclosamide is an “old” antihelminthic drug that uncouples mitochondria of intestinal parasites. Although recent studies demonstrated that niclosamide could be a potential anticancer agent, its poor water solubility needs to be overcome before further preclinical and clinical investigations can be conducted. Therefore, we evaluated a novel nanosuspension of niclosamide (nano-NI) for its effect against ovarian cancer. Nano-NI effectively inhibited the growth of ovarian cancer cells in which it induced a metabolic shift to glycolysis at a concentration of less than 3 μM in vitro and suppressed tumor growth without obvious toxicity at an oral dose of 100 mg/kg in vivo. In a pharmacokinetic study after oral administration, nano-NI showed rapid absorption (reaching the maximum plasma concentration within 5 min) and improved the bioavailability (the estimated bioavailability for oral nano-NI was 25%). In conclusion, nano-NI has the potential to be a new treatment modality for ovarian cancer and, therefore, further clinical trials are warranted.

  

참고문헌 (59)

  1. 1. 1 Siegel R Naishadham D Jemal A Cancer statistics, 2013 CA: a cancer journal for clinicians 2013 63 11 30 23335087 
  2. 2. 2 Romero I Bast RC Jr Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy Endocrinology 2012 153 1593 1602 22416079 
  3. 3. 3 Katsumata N Yasuda M Takahashi F Isonishi S Jobo T Aoki D Tsuda H Sugiyama T Kodama S Kimura E Ochiai K Noda K Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 2009 374 1331 1338 19767092 
  4. 4. 4 Ozols RF Bundy BN Greer BE Fowler JM Clarke-Pearson D Burger RA Mannel RS DeGeest K Hartenbach EM Baergen R Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study J Clin Oncol 2003 21 3194 3200 12860964 
  5. 5. 5 Campos SM Ghosh S A current review of targeted therapeutics for ovarian cancer J Oncol 2010 2010 149362 20069122 
  6. 6. 6 Baumann KH du Bois A Meier W Rau J Wimberger P Sehouli J Kurzeder C Hilpert F Hasenburg A Canzler U Hanker LC Hillemanns P Richter B A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy Ann Oncol 2012 23 2265 2271 22377563 
  7. 7. 7 Burger RA Brady MF Bookman MA Fleming GF Monk BJ Huang H Mannel RS Homesley HD Fowler J Greer BE Boente M Birrer MJ Liang SX Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 2011 365 2473 2483 22204724 
  8. 8. 8 Perren TJ Swart AM Pfisterer J Ledermann JA Pujade-Lauraine E Kristensen G Carey MS Beale P Cervantes A Kurzeder C du Bois A Sehouli J Kimmig R A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 2011 365 2484 2496 22204725 
  9. 9. 9 Wang TS Lei W Cui W Wen P Guo HF Ding SG Yang YP Xu YQ Lv SW Zhu YL A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer Indian J Cancer 2014 51 Suppl 3 e95 98 25818743 
  10. 10. 10 Chen K Huang YH Chen JL Understanding and targeting cancer stem cells: therapeutic implications and challenges Acta Pharmaco Sin 2013 34 732 740 
  11. 11. 11 Zhang S Balch C Chan MW Lai HC Matei D Schilder JM Yan PS Huang TH Nephew KP Identification and characterization of ovarian cancer-initiating cells from primary human tumors Cancer Res 2008 68 4311 4320 18519691 
  12. 12. 12 Blagosklonny MV A new science-business paradigm in anticancer drug development Trends Biotechnol 2003 21 103 106 12628364 
  13. 13. 13 Chong CR Sullivan DJ Jr New uses for old drugs Nature 2007 448 645 646 17687303 
  14. 14. 14 Yo YT Lin YW Wang YC Balch C Huang RL Chan MW Sytwu HK Chen CK Chang CC Nephew KP Huang T Yu MH Lai HC Growth inhibition of ovarian tumor-initiating cells by niclosamide Mol Cancer Ther 2012 11 1703 1712 22576131 
  15. 15. 15 Wang YC Chao TK Chang CC Yo YT Yu MH Lai HC Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells PloS one 2013 8 e74538 24058587 
  16. 16. 16 Osada T Chen M Yang XY Spasojevic I Vandeusen JB Hsu D Clary BM Clay TM Chen W Morse MA Lyerly HK Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations Cancer Res 2011 71 4172 4182 21531761 
  17. 17. 17 Li Y Li PK Roberts MJ Arend RC Samant RS Buchsbaum DJ Multi-targeted therapy of cancer by niclosamide: a new application for an old drug Cancer Lett 2014 349 8 14 24732808 
  18. 18. 18 Jin Y Lu Z Ding K Li J Du X Chen C Sun X Wu Y Zhou J Pan J Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species Cancer Res 2010 70 2516 2527 20215516 
  19. 19. 19 Ren X Duan L He Q Zhang Z Zhou Y Wu D Pan J Pei D Ding K Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway ACS Med Chem Lett 2010 1 454 459 24900231 
  20. 20. 20 Wieland A Trageser D Gogolok S Reinartz R Hofer H Keller M Leinhaas A Schelle R Normann S Klaas L Waha A Koch P Fimmers R Anticancer effects of niclosamide in human glioblastoma Clin Cancer Res 2013 19 4124 4136 23908450 
  21. 21. 21 Lu W Lin C Roberts MJ Waud WR Piazza GA Li Y Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway PloS one 2011 6 e29290 22195040 
  22. 22. 22 Whitesell JK The Merck Index, 12th Edition, CD-ROM (Macintosh): An encyclopedia of chemicals, drugs & biologicals J Am Chem Soc 1998 120 2209 2209 
  23. 23. 23 Chen H Yang Z Ding C Chu L Zhang Y Terry K Liu H Shen Q Zhou J Discovery of alkylamino tethered niclosamide derivatives as potent and orally bioavailable anticancer agents ACS Med Chem Lett 2013 4 180 185 23459613 
  24. 24. 24 Vasconcelos T Sarmento B Costa P Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs Drug Discov Today 2007 12 1068 1075 18061887 
  25. 25. 25 Sahoo SK Dilnawaz F Krishnakumar S Nanotechnology in ocular drug delivery Drug Discov Today 2008 13 144 151 18275912 
  26. 26. 26 Sosnik A Carcaboso AM Glisoni RJ Moretton MA Chiappetta DA New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery Adv Drug Deliv Rev 2010 62 547 559 19914315 
  27. 27. 27 Gomez-Orellana I Strategies to improve oral drug bioavailability Expert Opin Drug Deliv 2005 2 419 433 16296764 
  28. 28. 28 Bai MY Yang HC Fabrication of novel niclosamide-suspension using an electrospray system to improve its therapeutic effects in ovarian cancer cells in vitro Colloids Surf A Physicochem Eng Asp 2013 419 248 256 
  29. 29. 29 Shargel L Wu-Pong S Yu ABC Applied biopharmaceutics and pharmacokinetics 2005 McGraw-Hill Co: Inc Boston 
  30. 30. 30 Yi T Elson P Mitsuhashi M Jacobs B Hollovary E Budd TG Spiro T Triozzi P Borden EC Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects Oncotarget 2011 2 1155 1164 10.18632/oncotarget.563 22201704 
  31. 31. 31 Jeong da E Song HJ Lim S Lee SJ Lim JE Nam DH Joo KM Jeong BC Jeon SS Choi HY Lee HW Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis Oncotarget 2015 6 33046 33064 10.18632/oncotarget.5422 26426994 
  32. 32. 32 Zhang L Gu FX Chan JM Wang AZ Langer RS Farokhzad OC Nanoparticles in medicine: therapeutic applications and developments Clin Pharmacol Ther 2008 83 761 769 17957183 
  33. 33. 33 Liu YY Miyoshi H Nakamura M Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles Int J Cancer 2007 120 2527 2537 17390371 
  34. 34. 34 Wang S Su R Nie S Sun M Zhang J Wu D Moustaid-Moussa N Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals J Nutr Biochem 2014 25 363 376 24406273 
  35. 35. 35 Mozafari MR Pardakhty A Azarmi S Jazayeri JA Nokhodchi A Omri A Role of nanocarrier systems in cancer nanotherapy J Liposome Res 2009 19 310 321 19863166 
  36. 36. 36 Azim HA Jr de Azambuja E Colozza M Bines J Piccart MJ Long-term toxic effects of adjuvant chemotherapy in breast cancer Ann Oncol 2011 22 1939 1947 21289366 
  37. 37. 37 Uziely B Jeffers S Isacson R Kutsch K Wei-Tsao D Yehoshua Z Libson E Muggia FM Gabizon A Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies J Clin Oncol 1995 13 1777 1785 7602367 
  38. 38. 38 Mamot C Ritschard R Wicki A Stehle G Dieterle T Bubendorf L Hilker C Deuster S Herrmann R Rochlitz C Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study Lancet Oncol 2012 13 1234 1241 23153506 
  39. 39. 39 Sabnani MK Rajan R Rowland B Mavinkurve V Wood LM Gabizon AA La-Beck NM Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses Nanomedicine 2015 11 259 262 25200609 
  40. 40. 40 Sack U Walther W Scudiero D Selby M Kobelt D Lemm M Fichtner I Schlag PM Shoemaker RH Stein U Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer J Nati Cancer Inst 2011 103 1018 1036 
  41. 41. 41 Hanslick JL Lau K Noguchi KK Olney JW Zorumski CF Mennerick S Farber NB Dimethyl sulfoxide (DMSO) produces widespread apoptosis in the developing central nervous system Neurobiol Dis 2009 34 1 10 19100327 
  42. 42. 42 Arend RC Londono-Joshi AI Samant RS Li Y Conner M Hidalgo B Alvarez RD Landen CN Straughn JM Buchsbaum DJ Inhibition of Wnt/beta-catenin pathway by niclosamide: a therapeutic target for ovarian cancer Gynecol Oncol 2014 134 112 120 24736023 
  43. 43. 43 Li R You S Hu Z Chen ZG Sica GL Khuri FR Curran WJ Shin DM Deng X Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer PloS one 2013 8 e74670 24019973 
  44. 44. 44 Fonseca BD Diering GH Bidinosti MA Dalal K Alain T Balgi AD Forestieri R Nodwell M Rajadurai CV Gunaratnam C Tee AR Duong F Andersen RJ Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling J Biol Chem 2012 287 17530 17545 22474287 
  45. 45. 45 Nielsen SF Nordestgaard BG Bojesen SE Statin use and reduced cancer-related mortality N Engl J Med 2012 367 1792 1802 23134381 
  46. 46. 46 Kumar S Meuter A Thapa P Langstraat C Giri S Chien J Rattan R Cliby W Shridhar V Metformin intake is associated with better survival in ovarian cancer: a case-control study Cancer 2013 119 555 562 23208739 
  47. 47. 47 Robinson E Nandi M Wilkinson LL Arrowsmith DM Curtis ADM Richardson A Preclinical evaluation of statins as a treatment for ovarian cancer Gynecol Oncol 2013 129 417 424 23402903 
  48. 48. 48 Cairns RA Harris IS Mak TW Regulation of cancer cell metabolism Nat Rev Cancer 2011 11 85 95 21258394 
  49. 49. 49 Hanahan D Weinberg RA Hallmarks of cancer: the next generation Cell 2011 144 646 674 21376230 
  50. 50. 50 Tennant DA Duran RV Gottlieb E Targeting metabolic transformation for cancer therapy Nat Rev Cancer 2010 10 267 277 20300106 
  51. 51. 51 Zhao Y Butler EB Tan M Targeting cellular metabolism to improve cancer therapeutics Cell Death Dis 2013 4 
  52. 52. 52 Foley OW Rauh-Hain JA del Carmen MG Recurrent epithelial ovarian cancer: an update on treatment Oncology (Williston Park) 2013 27 288–294 298 23781692 
  53. 53. 53 Pfisterer J Plante M Vergote I du Bois A Hirte H Lacave AJ Wagner U Stahle A Stuart G Kimmig R Olbricht S Le T Emerich J Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG J Clin Oncol 2006 24 4699 4707 16966687 
  54. 54. 54 Aghajanian C Blank SV Goff BA Judson PL Teneriello MG Husain A Sovak MA Yi J Nycum LR OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 2012 30 2039 2045 22529265 
  55. 55. 55 Rose PG Blessing JA Ball HG Hoffman J Warshal D DeGeest K Moore DH A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 2003 88 130 135 12586591 
  56. 56. 56 Petru E Angleitner-Boubenizek L Reinthaller A Deibl M Zeimet AG Volgger B Stempfl A Marth C Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study Gynecol Oncol 2006 102 226 229 16443259 
  57. 57. 57 Liu KC Yo YT Huang RL Wang YC Liao YP Huang TS Chao TK Lin CK Weng SJ Ma KH Chang CC Yu MH Lai HC Ovarian cancer stem-like cells show induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor Oncotarget 2013 4 2366 2382 10.18632/oncotarget.1424 24280306 
  58. 58. 58 Loening AM Gambhir SS AMIDE: a free software tool for multimodality medical image analysis Mol Imaging 2003 2 131 137 14649056 
  59. 59. 59 Liao MH Shih CC Tsao CM Chen SJ Wu CC RhoA/Rho-kinase and nitric oxide in vascular reactivity in rats with endotoxaemia PloS one 2013 8 e56331 23457552 

원문보기

원문 PDF 다운로드

  • ScienceON :

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

DOI 인용 스타일

"" 핵심어 질의응답